logo
The Best Way to Drop an Egg Without Breaking It, According to Science

The Best Way to Drop an Egg Without Breaking It, According to Science

Gizmodo08-05-2025
Here's hoping Humpty Dumpty reads the news. In research out today, scientists have apparently figured out the safest way to drop an egg without it breaking.
Researchers at MIT conducted the study, published Thursday in Communications Physics. After nearly 200 experiments, the team determined that dropping an egg horizontally is more likely to keep it intact than a vertical drop—completely contrary to folk wisdom.
MIT and many other schools regularly host an 'egg drop challenge' for their students. The goal is simple enough: use some ingenuity and basic materials like toothpicks and twine to construct a contraption that will keep their eggs from breaking once dropped.
But according to study researcher and engineer Tal Cohen, both teachers and online sources will often also recommend that the egg stays vertical to further lower the risk of cracking. The underlying assumption behind this advice is that the egg's vertical structure resembles an arch, and arches are very good at redistributing the loads of energy (or force) placed on them.
'After a number of times doing this competition, we started to question the common notion. We weren't convinced that the static explanation, which applies to an arch, translates to the case of dynamic impact,' Cohen, an associate professor in the Sustainable Materials and Infrastructure department at MIT, told Gizmodo.
Cohen and her team took some of the eggs left behind at the end of a recent MIT challenge to test their hunch in the lab, but their initial experiments were inconclusive. So they decided to start a formal and more extensive project.
In total, they dropped 180 eggs either vertically or horizontally onto a hard surface. The eggs were dropped in rounds of 60 each at three different heights: 8, 9, and 10 millimeters (basically between 0.32 and 0.39 inches). And overall, the vertically dropped eggs fared worse. More than half of the vertical eggs broke when dropped 8 millimeters, for instance, compared to less than 10% of horizontal eggs. Further tests also showed that the horizontally dropped eggs could compress more before breaking than the vertically dropped ones.
The findings might not be world-changing, but they illustrate how our conventional wisdom can sometimes lead us astray, even the kind that's taught in science classrooms.
'People tend to have better intuition for stiffness and strength, which are important in statics. It is common that they refer intuitively to the redistribution of a load along the arch. However, when dynamics are involved, toughness is also an important quantity,' Cohen said. 'For example, consider two balls; one made of glass, and the other of rubber. The glass ball is stiffer and may have higher strength, but when dropped from a height, the glass ball is also more likely to break, while the rubber ball can deform to absorb the kinetic energy, without breaking.'
Cohen notes that there are plenty of things in both nature and engineering like eggs that have thin shells protecting their inner contents. So their research here could very well help 'influence how people think about these structures as well,' she said.
Personally, I'm just glad I'll have another reason to be mad at myself when I inevitably drop my next egg onto the kitchen floor while cooking—I should have remembered to keep it horizontal!
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Male birth control pill passes early safety test, with more trials underway
Male birth control pill passes early safety test, with more trials underway

Yahoo

time43 minutes ago

  • Yahoo

Male birth control pill passes early safety test, with more trials underway

When you buy through links on our articles, Future and its syndication partners may earn a commission. An experimental, hormone-free male birth control pill has just passed its first safety test in humans. The trial included 16 people and was only intended to test whether the drug reached adequate levels in the body, as well as whether it triggered any serious side effects, such as concerning changes in heart rate, hormone function, inflammation, mood or sexual function. Across the doses tested, no significant side effects were observed. That result tees up the pill to be tested in larger trials that will now look at both safety and efficacy. The results of the early safety trial, published Tuesday (July 22) in the journal Communications Medicine, are a critical first step toward getting the pill approved, Dr. Stephanie Page, an endocrinologist at the University of Washington School of Medicine who wasn't involved in the study, told Scientific American. "We really need more reversible contraceptive methods for men," she added. For the moment, the only male birth control options are condoms and vasectomies. The latter can be reversed, but the actual success rate of the reversal procedure varies widely in terms of how likely a person is to conceive a child afterward. If approved, the new pill would be the first drug in its class. "A safe and effective male pill will provide more options to couples for birth control," Gunda Georg, a professor in the University of Minnesota College of Pharmacy, where the drug molecule was developed, said in a statement released earlier this year following promising preclinical testing of the pill. Columbia University was also involved in the drug's development, along with the company YourChoice Therapeutics, which is overseeing the trials. Related: Why is there still no male birth control pill? "It will allow a more equitable sharing of responsibility for family planning and provide reproductive autonomy for men," Georg said. How the male birth control pill works The experimental pill, called YCT-529, is designed to pause sperm production by interrupting specific signals in the body. Specifically, the drug works by blocking a protein called "retinoic acid receptor alpha," which is known to play a key role in the formation and maturation of sperm. In the testes, the receptor would usually be activated by the insertion of a "key" — a vitamin A metabolite — but the drug stops this key from clicking into place. That, in turn, prevents the chain reaction that ends with sperm being made. Finding a compound with this effect required the scientists to closely examine the structure of the receptor when it's bound to its key, as well as test dozens of molecules to see which could block the interaction. In preclinical tests with male lab mice, the drug "elicited profound effects" on sperm production. It triggered reversible infertility within four weeks of use, showing 99% effectiveness at preventing pregnancy in the female mice the treated males mated with. When taken off the drug, the male mice's fertility was restored within about four to six weeks. Further tests in nonhuman primates returned similar results, with sperm counts falling dramatically within two weeks of starting the drug and fully recovering within 10 to 15 weeks of stopping the drug. These preclinical tests set the stage for the recent clinical trial in people. The trial included 16 males ages 32 to 59, all of whom had previously undergone vasectomies. This was done out of an abundance of caution, in case the experimental drug was to have any lasting impacts on fertility, Nadja Mannowetz, co-founder and chief science officer of YourChoice Therapeutics, told Scientific American. The participants were split into groups who received either placebo pills or a low or high dose of the drug. Most of the participants took the pill only after a period of fasting, but a subset were also given doses after a large meal, to see if that affected levels of the drug in the body. Across all of the doses and conditions tested, the levels of the drug in the body reached decent levels, but Mannowetz anticipates that, if approved, the final dose would be closest to the highest one tested: 180 milligrams. RELATED STORIES —Hormonal birth control may double risk of stroke, study finds —1st over-the-counter birth control pill approved by FDA —Blood clot risk linked to taking common painkillers alongside certain hormonal birth control Both the animal study and the human trial results suggest that the approved pill would likely be taken once a day, but further trials will confirm that dosing. And although no notable side effects emerged in this small trial, future trials with larger study cohorts will still need to monitor for these effects. "The positive results from this first clinical trial laid the groundwork for a second trial, where men receive YCT-529 for 28 days and 90 days, to study safety and changes in sperm parameters," the study authors wrote in their paper. That trial is already underway and again is looking at males who have already had vasectomies or who have made a firm decision not to father children. This article is for informational purposes only and is not meant to offer medical advice.

How Myeloma Plays Hide and Seek With CAR T Cells
How Myeloma Plays Hide and Seek With CAR T Cells

Medscape

time2 hours ago

  • Medscape

How Myeloma Plays Hide and Seek With CAR T Cells

TOPLINE: G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) occurs through biallelic genetic inactivation and hypermethylation-driven epigenetic silencing. Among 10 patients who relapsed, eight showed GPRC5D loss, while two had mixed expression. METHODOLOGY: Researchers conducted whole-genome sequencing (WGS) and whole-genome bisulfite sequencing (WGBS) analysis on MM samples from 10 patients who relapsed after GPRC5D CAR T-cell therapy. Analysis included CD138+ MM cells isolated from bone marrow samples with purity exceeding 80%, with tumor samples sequenced at 100× coverage and matched normal samples at 30× coverage. Investigators performed targeted bisulfite sequencing to evaluate methylation status of GPRC5D regulatory regions across seven MM cell lines, with library construction and sequencing conducted by specialized institutes. Patient characteristics included median age of 57.5 years (range, 44-66 years), equal gender distribution, and 90% having high-risk cytogenetic abnormalities. TAKEAWAY: Genetic alterations were identified in three cases: one with homozygous deletion in GPRC5D gene, another with biallelic loss in regulatory regions, and a third with homozygous deletions in both TNFRSF17 and GPRC5D after sequential anti-B-cell maturation antigen and anti-GPRC5D CAR T-cell therapies. Multiple hypermethylation sites were present in transcriptional regulatory elements of GPRC5D gene in five posttreatment MM samples, with no genetic changes detected at GPRC5D locus in seven cases. GPRC5D expression showed inverse correlation with methylation levels in regulatory regions of MM cell lines, with azacitidine treatment inducing GPRC5D messenger RNA and protein expression in hypermethylated MM cell lines. All 10 patients achieved complete response or better as best response with median time to best response of 2.5 months (range, 0.5-15.3 months), though median time to disease progression was 15.9 months (range, 3.0-26.5 months). IN PRACTICE: 'Our findings highlight that biallelic genetic inactivation and hypermethylation-driven epigenetic silencing are key mechanisms contributing to GPRC5D loss and treatment resistance,' wrote the authors of the study. SOURCE: The study was led by Mingshan Niu, Blood Diseases Institute, Xuzhou Medical University in Xuzhou, China. It was published online in Blood. LIMITATIONS: According to the authors, the structural variant deletions on chromosomes may be missed by 100× WGS in patients with a clone size less than 20%. The limit of detection for quantitative polymerase chain reaction ranged from 16 to 50 copies per reaction, indicating sensitivity limitations of these detection methods. Additionally, genetic alterations in the GPRC5D locus could either be acquired after CAR T-cell therapy or selected from preexisting clones, necessitating more sensitive detection methods for dynamic monitoring. DISCLOSURES: The research received support from the National Natural Science Foundation of China (82270181) and the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (21KJA320005). The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Second Brain Alert: Gut Tags Your Nutrients
Second Brain Alert: Gut Tags Your Nutrients

Medscape

time3 hours ago

  • Medscape

Second Brain Alert: Gut Tags Your Nutrients

At first glance, 'trusting your gut' may seem intuitive, irrational, or even unscientific. However, science confirms that the digestive system is indeed 'sensitive'; it contains its own autonomic network, known as the enteric nervous system, comprising approximately 100 million nerve cells. A study in Nature revealed that the gut's own enteric nervous system can not only detect nutrients but also distinguish between them, showing that it is far smarter than once believed. New research led by KU Leuven, Leuven, Belgium, researchers from the Translational Research in GastroIntestinal Disorders team shows that neurons in the intestinal wall respond to specific nutrients in a targeted manner. The study conducted on the intestinal tissue of mice showed that the intestine can differentiate between sugars, proteins, and fats. Each nutrient activates its own neurochemical network through reactions involving specific neurons. Using calcium imaging in the mouse jejunum, researchers found that nutrients activate specific groups of enteric neurons, but not directly. The epithelium, the surface tissue on the inside of the intestine, plays a key role in the detection of different nutrients. The tissue uses serotonin, a well-known neurotransmitter, to send signals to the nervous system. Signals move from the villus epithelium to the myenteric plexus and then to the submucosal plexus, revealing a clear communication pathway across the intestinal walls. 'What we're seeing is that the enteric nervous system doesn't just respond to pressure or stretching. It works in a much more targeted way depending on the specific nutrients in the intestine,' said Candice Fung, postdoctoral researcher and first author of the study. 'The precision with which the nervous system can differentiate between sugars, proteins, and fats proves how refined and intelligent this system is.' The LENS (Laboratory for Enteric Neuroscience) research group, led by Pieter Vanden Berghe, PhD, specialises in light microscopy for imaging live cells and tissues. Scientists use fluorescent markers that make neurons light up when activated. Thus, the processes in the enteric nervous system can be visualised in real time. 'When we talk about a 'gut feeling,' we shouldn't be dismissive when it comes to our digestive system and enteric nervous system. This research demonstrates a certain form of intelligence in the gut. This is why people sometimes refer to it as the 'second brain' or 'little brain.' But if you ask me, the enteric nervous system is too important and too sophisticated to be considered the 'little brother,'' said Berghe. This story was translated and adapted from MediQuality.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store